300mg Gemcabene ( DrugBank: Gemcabene )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 265 | 脂肪萎縮症 | 1 |
265. 脂肪萎縮症
臨床試験数 : 116 / 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03508687 (ClinicalTrials.gov) | March 13, 2018 | 3/4/2018 | Study of Gemcabene in Adults With FPLD | An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD) | Familial Partial Lipodystrophy;Hypertriglyceridemia;Fatty Liver;NASH - Nonalcoholic Steatohepatitis | Drug: 300mg Gemcabene;Drug: 600mg Gemcabene | Elif Oral | NULL | Completed | 18 Years | N/A | All | 5 | Phase 1/Phase 2 | United States |